Literature DB >> 10340723

Melatonin receptors in PC3 human prostate tumor cells.

E Gilad1, M Laufer, H Matzkin, N Zisapel.   

Abstract

Melatonin, secreted nocturnally by the pineal gland, can bind to human benign prostate epithelial cells and attenuate their growth and viability. In the present study, melatonin binding and responses were explored in the human steroid-independent PC3 prostatic tumor cells. PC3 cells bound 125I-melatonin with low affinity (Kd ca. 0.9 nM) at high as well as low cell density. Melatonin enhanced cGMP and 3H-thymidine incorporation at low, but attenuated them at high cell density. In addition, melatonin inhibited cAMP at low, but augmented it at high cell density. These effects were associated with an increase in cell count at low- but not high-density cultures. Pertussis toxin treatment suppressed 125I-melatonin binding and ablated all the effects of melatonin on 3H-thymidine incorporation, cAMP, and cGMP at both cell densities. Cholera toxin treatment failed to block the effects of melatonin on 3H-thymidine incorporation, but prevented the modulation by melatonin of cAMP at low and cGMP at high cell density. The cGMP analog 8-Br-cGMP, inhibited melatonin's effects on 3H-thymidine incorporation at both cell densities. H89, a protein kinase A inhibitor, prevented melatonin's effects on 3H-thymidine incorporation at low but not high cell density. These results provide the first demonstration of direct interaction of melatonin with hormone-insensitive prostate tumor cells. The melatonin receptors in the PC3 cells are coupled to pertussis toxin-sensitive G proteins to induce cell density-dependent changes in cGMP, cAMP, and cell growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340723     DOI: 10.1111/j.1600-079x.1999.tb00586.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  8 in total

1.  Self-Assessed Benefits of a Prostate Health Formulation on Nocturia in Healthy Males With Mild Lower Urinary Tract Symptoms: An Open Label Study.

Authors:  Steven P Hirsh; Marianne Pons; Steven V Joyal; Andrew G Swick
Journal:  Glob Adv Health Med       Date:  2020-11-27

Review 2.  WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Authors:  Zsofia Kiss; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2016-09-22       Impact factor: 5.678

3.  Gi and RGS proteins provide biochemical control of androgen receptor nuclear exclusion.

Authors:  Avi Rimler; Ralf Jockers; Zipora Lupowitz; Nava Zisapel
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

4.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

Review 5.  Melatonin: Pharmacology, Functions and Therapeutic Benefits.

Authors:  Sylvie Tordjman; Sylvie Chokron; Richard Delorme; Annaëlle Charrier; Eric Bellissant; Nemat Jaafari; Claire Fougerou
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

6.  Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells.

Authors:  Angela Calastretti; Giuliana Gatti; Valeria Lucini; Silvana Dugnani; Gianfranco Canti; Francesco Scaglione; Annamaria Bevilacqua
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

Review 7.  Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

Authors:  E S Schernhammer; K Schulmeister
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

Review 8.  Melatonin: an anti-tumor agent for osteosarcoma.

Authors:  Hadis Fathizadeh; Hamed Mirzaei; Zatollah Asemi
Journal:  Cancer Cell Int       Date:  2019-11-29       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.